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RESEARCH ARTICLE

Monitoring of Biodistribution and Persistence of
Conditionally Replicative Adenovirus in a Murine Model
of Ovarian Cancer Using Capsid-Incorporated mCherry
and Expression of Human Somatostatin Receptor
Subtype 2 Gene
Igor P. Dmitriev, Elena A. Kashentseva, Kenneth H. Kim, Qiana L. Matthews, Stephanie S. Krieger, Jesse J. Parry,
Kim N. Nguyen, Walter J. Akers, Samuel Achilefu, Buck E. Rogers, Ronald D. Alvarez, and David T. Curiel

Abstract
A significant limiting factor to the human clinical application of conditionally replicative adenovirus (CRAd)-based virotherapy is the
inability to noninvasively monitor these agents and their potential persistence. To address this issue, we proposed a novel imaging
approach that combines transient expression of the human somatostatin receptor (SSTR) subtype 2 reporter gene with genetic
labeling of the viral capsid with mCherry fluorescent protein. To test this dual modality system, we constructed the Ad5/
3D24pIXcherry/SSTR CRAd and validated its capacity to generate fluorescent and nuclear signals in vitro and following intratumoral
injection. Analysis of

64

Cu-CB-TE2A-Y3-TATE biodistribution in mice revealed reduced uptake in tumors injected with the imaging

CRAd relative to the replication–incompetent, Ad-expressing SSTR2 but significantly greater uptake compared to the negative CRAd
control. Optical imaging demonstrated relative correlation of fluorescent signal with virus replication as determined by viral genome
quantification in tumors. Positron emission tomography/computed tomography studies demonstrated that we can visualize
radioactive uptake in tumors injected with imaging CRAd and the trend for greater uptake by standardized uptake value analysis
compared to control CRAd. In the aggregate, the plasticity of our dual imaging approach should provide the technical basis for
monitoring CRAd biodistribution and persistence in preclinical studies while offering potential utility for a range of clinical
applications.

N THE PAST TWO DECADES, gene therapy has been
developed as a promising approach to combat a variety of
diseases. Over this time period, more than 1,700 clinical gene
therapy trials were conducted, with 65% addressing cancer.1
Adenoviral vectors have been used in 24% of clinical trials,
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followed by retroviral vectors (21%) and naked/plasmid
DNA (19%). Thus far, gene transfer efficiency has been
evaluated by obtaining tissue biopsies at predetermined times
posttreatment. This method of determining gene transfer
efficiency is undesirable due to its invasiveness and its
inability to generate a global picture of gene transfer because
it is limited to the small piece of tissue(s) examined. It is
evident that gene therapy trials would benefit from the ability
to determine the location of gene delivery vectors and
evaluate the magnitude of expression of the delivered genes
over time.
Human adenovirus2 (Ad) has been used extensively to
develop replication-deficient gene delivery vectors and
conditionally replicative adenovirus (CRAd) agents for
cancer treatment. We previously evaluated several gene
therapy strategies including oncolytic CRAd virotherapy for
ovarian cancer.3,4 This approach takes advantage of the
propensity of human Ad to infect and replicate in epithelial
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cells, the origin of most human cancers, while promoting
cell lysis to facilitate release of viral progeny.2 These features
have been exploited by a number of strategies aimed at
creating oncolytic CRAd vectors with increased selectivity
for cancer cells.5 We showed that the clinical utility of
CRAds derived from adenovirus serotype 5 (Ad5) for
oncolytic treatment of ovarian carcinoma is hampered by
inefficient infection of ovarian cancer cells due to the
paucity of coxsackievirus group B and Ad receptor (CAR),
the primary Ad5 receptor.6–8 To confer CAR-independent
virus tropism, we used genetic incorporation of RGD-4C
targeting peptide into Ad5 fiber knob domain9 or the knob
replacement for its counterpart from Ad serotype 310 that
recognizes an alternative receptor, desmoglein 2,11 which
appears to be more abundantly expressed in ovarian cancer
cells.12,13 These capsid modifications were employed to alter
tropism of CRAd Delta-24,14 which contains a 24-basepair
deletion in the E1A conserved region 2, allowing selective
replication within Rb-p16-deficient tumor cells,15 a defect
observed in most ovarian cancer cells.16,17 We showed that
Delta24-RGD and Ad5/3D24 CRAd derivatives exhibit
superior antitumor efficacy in murine models of carcinoma
of the ovary.18–20 Both of these CRAds have been translated
into phase I human clinical trials. These studies documented the safety of these agents.21,22 Although these studies
provided useful surrogate end points suggesting therapeutic
activity, the acquisition of additional data that would have
guided the rational development of improved CRAd agents
was limited by current vector design.
The ability to monitor virus biodistribution and
persistence could provide critical data about the tumortargeting efficacy of CRAd vectors and their safety in the
human context. On this basis, we considered strategies to
acquire these useful end points via imaging analysis to allow
the derivation of the maximal scientific value from
endeavored clinical trials. The major molecular imaging
modalities that are readily translatable to the clinic are
magnetic resonance imaging and nuclear imaging, including
positron-emission tomography (PET), gamma ray, or
single-photon emission computed tomography (SPECT).23
We previously demonstrated that the human somatostatin
(SST) receptor subtype 2 (SSTR2) can be used to assess the
efficacy of in vivo gene transfer in a clinical trial using a
replication-incompetent Ad vector by employing a Food and
Drug Administration–approved SST analogue reporter
probes for SPECT imaging.24 However, SSTR2 has not been
evaluated as an imaging reporter gene in the CRAd context.
As an alternative to conventional vector detection techniques, we developed a highly novel specific genetic labeling
system whereby an Ad vector incorporates a fusion between

capsid protein IX and imaging reporter.25–28 We also
demonstrated that genetic capsid labeling with fluorescent
proteins25 allows direct real-time analysis of in situ virus
localization using noninvasive optical imaging29,30 in preclinical cancer models, thus providing a promising approach
for the dynamic assessment of oncolytic CRAd function in
vivo. On the basis of these considerations, we sought to design
a CRAd agent that also embodies the ‘‘double imaging’’
capacity we defined in our foregoing studies. To this end, we
engineered the Ad5/3D24 CRAd to display mCherry
fluorescent protein at the pIX locale while expressing the
SSTR2 gene in the E3 region (Figure 1). We validated the
capacity of the constructed Ad5/3D24pIXcherry/SSTR CRAd
to generate fluorescent and nuclear signals in a murine model
of subcutaneous ovarian tumor xenografts compared to
replication-deficient Ad5/3-SSTRpIXcherry vector and Ad5/
3D24pIXcherry CRAd, thus demonstrating the potential
utility of our double imaging approach for preclinical and
human clinical employ. This novel linkage of imaging
modalities provides the potential to dramatically enhance

Figure 1. Graphical representation of Ad vectors used in the study.
The genomes of Ad5/3D24pIXcherry/SSTR (1), Ad5/3D24pIXcherry
(2), and Ad5/3D24 (4) CRAd vectors and replication-incompetent
Ad5/3-SSTRpIXcherry (3) vector are shown. The CRAd vectors (1, 2,
and 4) have a deletion of 24 nucleotides (D24) in the early E1A gene
(E1A) to allow selective replication in tumor cells with an pRb
mutation. The protein IX (pIX) gene is modified in all three vectors to
encode the C-terminal mCherry fluorescent protein (pIX-cherry). All
three vectors encode a chimeric fiber protein (5/3 fiber) containing tail
and shaft regions of Ad5 fiber fused with knob domain of Ad3. Ad5/
3D24pIXcherry/SSTR vector contains gene encoding human SSTR2,
which is incorporated in place of the deleted E3 region (DE3), under
transcriptional control of Ad major late promoter. Ad5/3-SSTRpIXcherry
vector has SSTR2 gene under the control of the human cytomegalovirus
immediate-early promoter (Pcmv) incorporated in place of the early E1
gene region (DE1). Ad5/3D24pIXcherry serves as E3-deleted control CRAd
lacking SSTR2 transgene.
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the analytical data acquired in the context of the expending
repertoire of oncolytic virotherapy trials.

Materials and Methods
Cells
The 293 human kidney cell line transformed with Ad5
DNA was purchased from Microbix (Toronto, Ontario).
The 911 human embryonic retinoblasts derived by
transformation with a plasmid containing 79 to 5,789
basepairs of the Ad5 genome31 were obtained through
Crucell Holland B.V. (Leiden, the Netherlands). The
human ovarian carcinoma cell line SKOV3.ip1 was
obtained from Janet Price (MD Anderson Cancer Center,
Houston, TX). The derivation of a human non–small cell
lung cancer line, A-427#7, stably transfected with a
hemagglutinin-tagged human SSTR2, was described previously.32 All cell lines were grown at 37uC in media
recommended by the suppliers in a humidified atmosphere of 5% CO2.
Construction of Ad Vectors
The construction of Ad5/3D24 CRAd, which contains a 24nucleotide deletion from basepair 923 to 946 corresponding
to the amino acid sequence 122 LTCHEAGF129 of the E1A
protein necessary for Rb protein binding14 and has the Ad
serotype 3 knob domain incorporated into the Ad5 fiber, was
described previously.19,22 The Ad5/3D24 CRAd was engineered to encode mCherry fluorescent protein fused to the Cterminus of a minor capsid protein IX as described recently,30
resulting in generation of Ad5/3D24pIXcherry CRAd. The
genome of Ad5/3D24pIXcherry/SSTR CRAd was generated as follows. First, the SSTR2 gene obtained from the
pAChSSTr2 plasmid33 was cloned into pShuttlE3 plasmid34
between BamHI and SalI restriction sites downstream of the
kanamycin gene and in the same orientation as the downstream fiber gene, and the resultant plasmid was linearized
and used for homologous recombination with pAdEasy-1
rescue plasmid35 in Escherichia coli BJ5183 cells as previously
described.34 The recombinant pAdEasy(E3/SSTR2) plasmid
containing both SSTR2 and kanamycin genes incorporated in
place of the deleted E3 region was selected using kanamycin.
Subsequently, kanamycin was excised with the two surrounding SwaI sites, and after self-ligation of pAdEasy(E3/SSTR2)
plasmid, it was retransformed into E. coli DH10B using
ampicillin selection. The Ad5/3D24pIXcherry/SSTR genome
was generated by homologous recombination between
pAdEasy(E3/SSTR2) and pSlD24-pIX-mCherry plasmids
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essentially as described elsewhere.30 To construct replicationdeficient Ad5/3-SSTRpIXcherry vector, we employed
pShSSTR2-IXmCherry plasmid, which was generated by
replacing a 1,654-basepair SacII fragment in pShuttleCMVHAhSSTr2 plasmid33 with SacII fragment (2,408 basepairs) isolated from pSlD24-pIX-mCherry,30 for homologous
recombination with pAdEasy-1-derived rescue plasmid
AdEz-F5/330 in E. coli BJ5183 cells.
The constructed plasmids containing viral genomes were
validated by polymerase chain reaction (PCR), restriction
analysis, and partial sequencing and were then linearized
with PacI to release the inverted terminal repeats of the viral
genomic DNA and then used to transfect 293 cells to rescue Ad5/3D24pIXcherry/SSTR CRAd and replicationincompetent Ad5/3-SSTRpIXcherry vector. The newly
rescued Ad vectors as well as Ad5/3D24pIXcherry and
Ad5/3D24 CRAd were propagated on 911 cells,31 purified by
centrifugation on CsCl gradients according to standard
protocol, and dialyzed against phosphate-buffered saline
(PBS) (8 mM Na2HPO4, 2 mM KH2PO4 [pH 7.4], 137 mM
NaCl, 2.7 mM KCl) containing 10% glycerol. The titers of
physical viral particles were determined by the methods of
Maizel and colleagues.36 The titers of infectious viral
particles were determined by plaque assay using 293 cells
as described by Mittereder and colleagues.37 The ratios of
viral particles to plaque-forming units (pfu) determined for
Ad5/3D24pIXcherry/SSTR, Ad5/3D24pIXcherry, Ad5/3D24,
and Ad5/3-SSTRpIXcherry vector were 37, 29, 25, and 42,
respectively.
Indirect Immunofluorescence
We employed mouse monoclonal antibody (mAb) IgG2A,
which was generated against intracellular domain of
human SSTR2 (amino acids 1–369, Accession # P30874),
purchased from Neuromics Antibodies (Edina, MN), to
evaluate the SSTR2 expression in SKOV3.ip1 cells infected
with generated Ad vectors by indirect immunofluorescence
assay using flow cytometry as follows. The SKOV3.ip1cell
monolayers grown in a six-well plate (1 3 106 cells/well)
were infected with Ad5/3D24pIXcherry/SSTR CRAd or
replication-incompetent Ad5/3-SSTRpIXcherry vector at a
multiplicity of infection (MOI) of 100 viral particles/cell
and incubated in culture medium containing 5% fetal
bovine serum (FBS) at 37uC in a humidified atmosphere
of 5% CO2 for 24, 36, 48, and 96 hours. Infected and
uninfected control (mock) cell monolayers were harvested
in 1 mL/monolayer PBS and centrifuged for 5 minutes at
1,000 RPM. Cell pellets were resuspended in 1 mL of icecold 70% ethanol and incubated on ice for 2 hours or
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overnight to fix soluble intracellular antigens. Cells were
aliquoted into 5 mL polystyrene round-bottomed tubes
(2.5 3 105 cells/tube) and centrifuged for 5 minutes at
1,500 RPM, and cell pellets were resuspended in 4 mL PBS.
This step was repeated to wash away any excess ethanol;
cells were resuspended in 125 mL PBS containing 0.1%
Triton X-100 and incubated in a 37uC water bath for
15 minutes to permeabilize cell membranes. Cells were
centrifuged for 5 minutes at 1,500 RPM, cell pellets were
resuspended in 2 mL fluorescent-activated cell sorting
(FACS) buffer (PBS containing 0.5% bovine serum
albumin [BSA], 0.1% NaN3, 0.1% Triton X-100), and
cells were pelleted again. Cells were resuspended at a
concentration of 2 3 106 cells/mL in a 100 mL/tube FACS
buffer containing human SSTR2 mAb at a concentration of 5 mg/mL and incubated at 4uC for 1 hour using a
plate shaker. An isotype-matched normal mouse IgG2A
(5 mg/mL) was used as a negative control. Cells were
diluted in 4 mL FACS buffer, centrifuged as above,
resuspended in FACS buffer containing the secondary
Alexa 488–labeled goat antimouse antibody (Molecular
Probes, Eugene, OR) at a concentration of 5 mg/mL, and
incubated at 4uC for 1 hour using a plate shaker. Cells were
washed with FACS buffer by centrifugation as above prior
to flow cytometry analysis. Cell samples were analyzed on a
BD Biosciences FACSAria (San Jose, CA) using the 488 nm
blue laser with the filter set for fluorescein isothiocyanate,
and 104 events were acquired per each cell specimen. Data
were expressed as the geometric mean fluorescence
intensity of the entire gated population. The positive cell
population was determined by gating the right-hand tail of
the distribution of the negative control sample for each
time point postinfection at 1%.
Western Blot Analysis
Samples of CsCl-purified Ad vectors were boiled in
Laemmli loading buffer, and 1.0 3 109 viral particles of
each virus were loaded on a 4 to 20% gradient sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDSPAGE) gel (Pierce, Rockford, IL). Electrophoretically
resolved viral proteins were transferred to a polyvinylidene
fluoride (PVDF) membrane and analyzed for the presence
of modified pIX-mCherry or chimeric 5/3 fiber proteins
using anti-pIX polyclonal rabbit serum or mAb 4D2
against the fiber tail region, respectively, as we described
previously.38 All primary antibodies were used at a dilution
of 1:1,000 for overnight incubation at 4uC. Bound rabbit
antibodies and mouse mAb were detected with a secondary
goat antirabbit or goat antimouse antibody conjugated

with alkaline phosphatase (Sigma, St. Louis, MO) and
developed with an alkaline phosphatase substrate kit (BioRad Laboratories, Hercules, CA).
Analysis of Expression of pIX-mCherry Protein
The SKOV3.ip1cell monolayers grown in a 24-well plate (3 3
105 to 5 3 105 cells/well) were incubated with each Ad vector
at an MOI of 0.3, 1.0, and 3 pfu/cell in 200 mL of culture
medium containing 2% FBS. The infection medium was
aspirated, and then cells were washed with PBS and incubated
in phenol red–free medium containing 5% FBS at 37uC
to allow reporter gene expression. The fluorescent light
intensities in cell monolayers were measured in the multifunctional Synergy HT plate reader (Bio-Tek Instruments,
Winooski, VT) using 560 nm emission and 620 nm excitation
filters. The data are presented as relative fluorescent units
(RFUs) detected on days 2, 3, 4, 5, 6, and 7 postinfection in
triplicate infected cells after the background light signal
detected in uninfected cells was subtracted.
Analysis of Oncolytic CRAd Effects
Monolayers of SKOV3ip.1 cells grown in 96-well plates
(3 3 103 to 5 3 103 cells/well) were infected in triplicate
with Ad5/3D24pIXcherry/SSTR, Ad5/3D24pIXcherry, and
Ad5/3D24 CRAd or control replication-deficient Ad5/3SSTRpIXcherry vector at MOI values ranging from 0.015
to 15 pfu/cell. The decrease in cell viability due to the virusinduced cell killing was measured 7 days postinfection using
the Cell Proliferation Assay (Promega Corporation, Madison,
WI) as recommended by the manufacturer. Assay was
performed by adding 10 mL CellTiter 96 AQueous One
Solution Reagent directly to culture wells containing red
phenol red–free medium supplemented with 2% FBS,
incubating for 2 hours, and then recording the absorbance
at 490 nm with a plate reader (Synergy HT, Bio-Tek
Instruments). The data are presented as the percentages of
viable cells in monolayers infected with each viral dose that
were determined with respect to the uninfected control set as
100%. To assess the cytopathic effects induced by virus
propagation, SKOV3.ip1cells grown in a 24-well plate (3 3
105 to 5 3 105 cells/well) were infected in triplicate with each
Ad vector at MOI values ranging from 0.015 to 15 pfu/cell.
Plates were incubated for 7 days at 37uC, and the cell
monolayer integrity was assessed by staining attached cells
with crystal violet and then scanning wells using a Synergy
HT plate reader (Bio-Tek Instruments) set at 565 nm. The
absorbance values detected in monolayers infected with each
viral dose were used to calculate the percentage of cell density
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in infected cell monolayers with respect to the uninfected
control.
Competitive Binding Assay
The maximum number of binding sites (Bmax) values of
SKOV3.ip1 cells infected with CRAd or replicationdeficient vector expressing SSTR2 were determined by
using a competitive binding assay with 125I-Tyr11-SST-14
(PerkinElmer, Boston, MA). To this end, cells were
infected with Ad5/3D24pIXcherry/SSTR CRAd or Ad5/3SSTRpIXcherry vector at an MOI of 100 viral particles/cell,
and membrane preparations were made 36 hours postinfection as previously described.39 Protein concentrations
were determined using the Pierce Non-Reducing Agent
Compatible Kit (Rockford, IL). The membrane preparations
were diluted in binding buffer (50 mM Tris-Cl [pH 7.4],
5 mM MgCl2, 0.1% BSA, 0.5 mg/mL aprotinin, 200 mg/mL
bacitracin, 10 mg/mL leupeptin, 10 mg/mL pepstatin) to
obtain a concentration of 25 mg per 100 mL. A 96-well
Multiscreen Durapore filtration plate (Millipore, Bedford,
MA) pretreated with 0.1% polyethyleneimine via vacuum
manifold aspiration was then washed with 300 mL of wash
buffer (10 mM HEPES, 1 mM ethylenediaminetetraacetic
acid [EDTA], 5 mM MgCl2, 0.1% BSA) before adding
100 mL of each membrane preparation in triplicate per
concentration of blocking reagent. The wells were then
washed three times with wash buffer. Various concentrations
of Tyr11-SST-14 (Bachem, Torrance, CA) blocking reagent,
ranging from 0.01 to 55 nM, were then added to the wells in
triplicate in a volume of 10 mL for both Ad5/3D24pIXcherry/
SSTR and Ad5/3-SSTRpIXcherry membrane preparation.
125
I-Tyr11-SST-14 ligand (PerkinElmer) was diluted in
binding buffer to < 0.04 nM (< 10,000 CPM per 100 mL),
which was then added to each well. The blocking reagent and
radioligand were incubated with shaking for 1 hour at room
temperature. All wells were washed twice with wash buffer,
and all remaining liquid was removed via vacuum manifold.
The membranes, once dry, were placed in individual tubes,
and the bound radioactivity was determined using a Packard
II gamma counter (PerkinElmer). The data were entered
into GraphPad Prism 4 (La Jolla, CA) to generate
homologous competitive binding curves using the one-site
homologous competition with depletion equation, and Bmax
values were calculated from the curves.
Biodistribution
All animal studies were performed in accordance with the
Guidelines for the Care and Use of Research Animals
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approved by the Animal Studies Committee at Washington
University. Homozygous Nude-Foxn1 nu/nu female athymic
nude mice (Harlan Laboratories, Indianapolis, IN), approximately 6 to 8 weeks of age, were subcutaneously implanted
on the rear right and left flanks with SKOV3.ip1 cells, 107 cells
per injection. Approximately 2 weeks following implantation,
tumor volumes reached 0.5 to 1 cm3 and the animals were
randomized based on size to form three groups (n 5 12 mice
per group) and injected intratumorally with 3 3 1010 viral
particles/tumor of Ad5/3-SSTRpIXcherry, Ad5/3D24pIXcherry/
SSTR, or Ad5/3D24pIXcherry. Injections of 64Cu-CB-TE2AY3-TATE (185 kBq, 5 mCi, 5 ng), which was prepared
according to standard literature protocols,40,41 were performed
via the tail vein in five mice from each group on days 4 and 8
following the virus admimistration, and the animals were then
sacrificed 4 hours following injection. The blood, liver, kidney,
spleen, pancreas, adrenals, muscle, bone, tail, and tumor
nodules were collected, weighed, and counted in a gamma
counter. The percent injected dose per gram (%ID/g) was
calculated based on the corrected radioactivity for each sample
compared to a standard, which was representative of the
injected dose.
Optical Imaging
Mice bearing subcutaneous tumor xenografts were injected
with Ad5/3-SSTRpIXcherry, Ad5/3D24pIXcherry/SSTR, or
Ad5/3D24pIXcherry as described above, and five mice from
each group were subjected to noninvasive optical imaging of
fluorescent light signal. In vivo imaging of the mice was
performed with a multimodal imaging system (In-Vivo MS
FX Pro, Bruker, Woodridge, CT) 7 days after virus injection.
Mice were placed in the imaging chamber (dorsal side
down) and maintained with 2% isoflurane gas anesthesia at
a flow rate of approximately 0.5 to 1 L/min per mouse. For
mCherry signal detection, multispectral imaging was
performed using xenon lamp excitation with 440, 460,
480, 510, 535, and 550 (6 20) nm optical band-pass filters,
and emission was captured with a cooled charge-coupled
device (CCD) camera after a 600 6 35 nm band-pass
emission filter (em600WA, Bruker). The acquisition
time was 10 seconds per image. Spectral separation of
MCherry fluorescence from background autofluorescence
and region of interest (ROI) analysis were performed using
Molecular Imaging software (Bruker). Average fluorescence
signal from individual tumor ROI were reported in arbitrary
units.
Fluorescence microscopy was employed to visualize
mCherry-positive cells in the tumor samples extracted
from mice 6 days after injection of Ad5/3D24pIXcherry/
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SSTR or control Ad5/3D24pIXcherry CRAd. The samples
of tumor tissue were minced using blades, and 30 mL
aliquots were placed on glass slides under coverslips
(Fisher Scientific, Pittsburgh, PA). Microscopy was
performed with an inverted IX-70 fluorescence microscope
(Olympus, Melville, NY) equipped with a Magnifire digital
CCD camera (Optronics, Goleta, CA). Images were
acquired with a 3100 objective using 1-second exposure.

divided by the nCi injected (decay corrected to the scan start
time) and multiplied by the mouse weight.
Statistical Analysis
All data are presented as the mean 6 SD. The Student twotailed t-test was used to determine statistical significance at
the 95% confidence level, with p # 0.05 being considered
significantly different.

Ad Genome Quantification in Tumors
The tumor nodules that were frozen following biodistribution assay were used to determine virus persistence in
tumor xenografts 4 and 8 days after virus injection. The
tumor nodules were mechanically homogenized using
zirconia/silica beads and Mini-Beadbeater-8 (BioSpec
Products, Bartlesville, OK) set at maximum speed during
two 30-second intervals. Total DNA was purified from
25 mg of homogenized tumor tissue using a QIAamp DNA
Mini Kit (Qiagen, Valencia, CA) as recommended by the
manufacturer. The levels of viral genome content were
determined in triplicate DNA samples extracted from
each tumor by real-time PCR analysis using a Light Cycler
480 System (Roche Diagnostics, Indianapolis, IN) with
TaqMan primers and probe designed for the Ad hexon
gene. The resultant viral genome copy number was
normalized by the amount of cellular DNA, which was
determined in the same sample with primers and probe
specific for human b-actin (housekeeping gene) using
duplexing TaqMan PCR settings.
MicroPET/CT Imaging Studies
Mice were implanted with SKOV3ip.1 tumors on the
axillary thorax and allowed to grow as described above. The
mice (n 5 3) were injected intratumorally with 3 3 1010
viral particles/tumor of Ad5/3D24pIXcherry/SSTR or Ad5/
3D24pIXcherry followed by intravenous injection of
64
Cu-CB-TE2A-Y3-TATE 4 days later (4.1 MBq [110 mCi];
175 ng). One and 4 hours after injection, the mice were
anesthetized with 1 to 2% isoflurane, positioned supine, and
imaged on microPET FOCUS 220 or Inveon PET smallanimal scanners (Siemens Medical Solutions, Malvern, PA).
The PET acquisition times were 10 minutes. The images
were reconstructed with an ordered-subset estimation
maximization (OSEM) algorithm, which included corrections for scatter and attenuation. ROI were drawn to
encompass the entire tumor to determine the maximum
activity concentration (nCi/cc) in the tumor. To calculate
the standardized uptake values (SUVs), the nCi/cc was

Results
Construction and Molecular Validation of Ad Vectors
In the current study, we designed and constructed four
vectors, which are illustrated in Figure 1. The previously
described Ad5/3D24 CRAd19 was engineered to encode
mCherry fluorescent protein fused to the C-terminus of a
minor capsid protein IX as well as SSTR2 transgene
incorporated in place of the deleted E3 region. This newly
generated Ad5/3D24pIXcherry/SSTR CRAd containing two
imaging reporters was used along with control vectors to
validate our hypothesis. The parental Ad5/3D24 CRAd and its
pIX-modified derivative, Ad5/3D24pIXcherry, which was
generated as described previously,30 were employed as control
CRAds (see Figure 1) lacking either both transgenes or SSTR2,
respectively. To evaluate if an oncolytic effect of CRAd can
interfere with expression of encoded imaging transgenes in
infected cells, we constructed Ad5/3-SSTRpIXcherry vector to
serve as a replication-deficient control. Ad5/3-SSTRpIXcherry
vector contains pIX-fused mCherry, whereas the SSTR2 gene
placed under transcriptional control of cytomegalovirus
(CMV) promoter is incorporated in the deleted E1 region
(see Figure 1).
To assess the efficiency of incorporation of the
fluorescent label into viral capsid, we used Western blot
to detect pIX-cherry fusion protein in virus preparations
purified by CsCl-gradient centrifugation. As can be seen in
Figure 2A, the constructed Ad5/3D24pIXcherry/SSTR and
Ad5/3-SSTRpIXcherry vectors contain a protein band of
similar size to the control Ad5/3D24pIXcherry virus. This
protein band was developed with anti-pIX polyclonal antibody and corresponds to a molecular mass of 46.8 kDa,
as expected for polypeptide IX fused with mCherry. A
similar intensity of this band detected in newly generated
and control virus samples, which were normalized by viral
particle number, indicates a relatively efficient incorporation
of fluorescent label into assembled Ad5/3D24pIXcherry/
SSTR and Ad5/3-SSTRpIXcherry virions compared to the
Ad5/3D24pIXcherry positive control. A minor protein band
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Figure 2. A, Analysis of incorporation of pIX-cherry fusion protein into viral capsid. Purified samples of Ad5/3D24pIXcherry/SSTR (lane 1), Ad5/
3-SSTRpIXcherry (lane 2), Ad5/3D24pIXcherry (lane 3), and Ad5/3D24 (lane 4) control vector were boiled in Laemmli sample buffer and run on 4
to 20% gradient SDS-PAGE. Viral proteins were transferred to PVDF membrane and incubated with either rabbit antiserum against Ad5 pIX (top
panel) or 4D2 monoclonal antibody against Ad5 fiber tail (bottom panel). Molecular masses of Precision Plus marker proteins (M) are indicated in
kilodaltons (kD) on the left. B, Monitoring of Ad5/3D24pIXcherry/SSTR infection in vitro. Monolayers of SKOV3ip.1 cells plated in a 96-well plate
were infected with Ad5/3D24pIXcherry/SSTR or Ad5/3D24pIXcherry CRAd vector at the multiplicity of infection of 0.3, 1, and 3 pfu/cell. The
persistence of CRAd in infected cells was monitored for 7 days postinfection based on virus-mediated expression of capsid protein IX fused with
the C-terminal mCherry fluorescent protein. The fluorescent light intensity was measured with a plate reader using 560 nm emission and 620 nm
excitation filters, and relative fluorescent units (RFU) detected in infected cells are presented after subtracting the background light signal detected
in uninfected cells. Each data point represents the cumulative mean 6 SD (some error bars are smaller than the symbols).

(approximately 25 kDa), which was detected in all three
pIX-modified viruses, appears to represent the proteolytic
degradation of pIX-cherry fusion protein due to the presence
of adenoviral protease cleavage site within fluorescent protein
sequence, as we described previously.42
Analysis of Ad-Mediated Expression of pIX-mCherry
Fusion
The capacity of pIX-fused mCherry protein to serve as a
reporter for optical imaging of Ad amplification was
evaluated by infecting the human ovarian cancer cell line
SKOV3.ip1 with CRAd or replication-incompetent Ad
vector encoding pIX-cherry and measuring fluorescent
light intensity at various time points postinfection using a
plate reader. Figure 2B illustrates the time course of
fluorescent signal development in cell monolayers infected
at various MOI with either Ad5/3D24pIXcherry/SSTR or
control Ad5/3D24pIXcherry CRAd. Both CRAd vectors
demonstrated a consistent increase in fluorescent light
intensity, which correlated with virus amplification and
spread of the viral progeny throughout the cell monolayer.
Fluorescent cells were observed in SKOV3.ip1 cell monolayers infected with nonreplicating Ad5/3-SSTRpIXcherry

vector; however, due to a lack of virus amplification, the
overall signal intensity was very low and could not be
distinguished from background autofluorescence (data not
shown). We noticed the significant increase in fluorescent
signal mediated by Ad5/3D24pIXcherry control at later
time points (MOI of 0.3 and 1.0 pfu/cell) and early time
points (MOI of 3 pfu/cell) postinfection compared to Ad5/
3D24pIXcherry/SSTR, which can be attributed to higher
pIX-cherry expression due to more efficient Ad5/3D24pIXcherry amplification. These data are consistent with
our previous reports29,30,42 and demonstrate the utility of
viral capsid labeling with fluorescent tags for identification
of infected cells and real-time analysis of CRAd amplification dynamics to allow noninvasive monitoring of oncolytic
virus spread by an optical imaging approach.
Analyses of Ad-Mediated SSTR2 Gene Expression
To compare the SSTR2 expression mediated by CRAd and
replication-deficient Ad, we carried out flow cytometry
with antibody against intracellular SSTR2 domain to assess
the overall SSTR2 levels in SKOV3.ip1 cells at various
times postinfection. As shown in Figure 3A, both Ad5/
3D24pIXcherry/SSTR and Ad5/3-SSTRpIXcherry vector
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Figure 3. Time course of virusmediated expression of SSTR2 protein. SKOV3ip.1 cells were infected
with 100 viral particles/cell of Ad5/
3D24pIXcherry/SSTR or Ad5/3-SSTRpIXcherry vector and were analyzed by
flow cytometry at various time points
postinfection for the levels of SSTR2
expression. Cells were harvested at the
indicated time points, fixed, permeabilized, and incubated with primary
monoclonal antibody against intracellular SSTR2 domain or mouse IgG
isotype control followed by the secondary Alexa 488–labeled antimouse
antibody and FACS assay. A, Flow
cytometry histogram overlays show an
increase in the mean fluorescence
detected in SKOV3ip.1 cells due to the
increase in SSTR2 expression level 24
(orange), 36 (green), 48 (blue), and 96
(red line) hours postinfection with Ad5/
3D24pIXcherry/SSTR (upper panel) or
Ad5/3-SSTRpIXcherry vector (lower
panel) compared to the mock-infected
cell control (black line). B, Quantification of the percentage of SKOV3ip.1
cells showing increased expression of
SSTR2 protein (upper panel) based on
increased mean fluorescent intensity
levels (lower panel) determined at 24,
36, 48, and 96 hours postinfection with
Ad5/3D24pIXcherry/SSTR or Ad5/3SSTRpIXcherry vector. FITC 5 fluorescein isothiocyanate.

provided the highest percentages of SSTR2-positive cells at
48 to 96 hours postinfection. Although both vectors
showed a marked increase in SSTR2 expression compared
to the background level detected in uninfected SKOV3.ip1,
infection with Ad5/3D24pIXcherry/SSTR CRAd resulted
in a 2.6- to 8.3-fold higher percentage of SSTR2overexpressing cells, with significantly increased mean
fluorescent intensity, compared to Ad5/3-SSTRpIXcherry
vector (Figure 3B). This overall augmentation of SSTR2
expression achieved by Ad5/3D24pIXcherry/SSTR with
respect to Ad5/3-SSTRpIXcherry vector can be attributed
to an SSTR2 gene copy number increase due to replication
of the CRAd genome in infected SKOV3.ip1 cells.
To examine the SST-binging capacity of SSTR2 overexpressed via CRAd or nonreplicating Ad infection, we
carried out competitive binding assays. To this end, we
used cellular membranes isolated 36 hours postinfection
of SKOV3.ip1 cells infected with 100 viral particles/cell
of Ad5/3D24pIXcherry/SSTR, Ad5/3-SSTRpIXcherry, and
various control vectors to measure binding with 125Ilabeled Tyr11-SST-14 analogue in the presence or absence
of unlabeled Tyr11-SST-14 blocking peptide.39 As shown in

Figure 4A, the detected binding level to the membranes of
Ad5/3D24pIXcherry/SSTR-infected cells was equivalent to
the A427-7 cell line derived to overexpress SSTR232 and
two times higher compared to Ad5/3-SSTRpIXcherryinfected cells. These binding signals were proven to be
SSTR2 specific as they were blocked by unlabeled Tyr11SST-14 peptide to the background level (see Figure 4A)
detected in mock-infected cells or cells infected with
control Ad vectors that did not contain the SSTR2 gene. In
addition, the expression levels of SSTR2 quantified in
cells infected with either Ad5/3D24pIXcherry/SSTR or
Ad5/3-SSTRpIXcherry were calculated as Bmax values of
3.8 pmol/mg and 2.0 pmol/mg, respectively (Figure 4B).
These data are in agreement with flow cytometry analysis
(see Figure 3) and demonstrate that greater expression of
SSTR2 when using the CRAd is translated into almost a
twofold increase in the number of functional receptor
molecules displayed on the membranes of infected cells
compared to the replication-deficient Ad5/3-SSTRpIXcherry.
These results indicate that the oncolytic property of Ad5/
3D24 CRAd does not interfere with the imaging reporter
fidelity in vitro.
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postinfection. The values of cell viability and density were
determined at various MOI and presented in Figure 5
show the somewhat reduced cytopathic effects of Ad5/
3D24pIXcherry/SSTR compared to Ad5/3D24pIXcherry
control and more significant loss of cytotoxicity with
respect to the parental Ad5/3D24 CRAd. This assay demonstrated that transgene incorporation into viral genome
combined with capsid protein IX modification to express
imaging reporters may negatively affect the oncolytic
potency of CRAd vector.

Detection of SSTR2 Expression Following
Intratumoral Virus Injection

Figure 4. Validation of CRAd to mediate expression of functional
SSTR2. A, Membrane preparations were made from SKOV3.ip1
cells that were infected 2 days earlier with 100 viral particles/cell of
Ad5/SSTRpIXcherry, Ad5/3-GFP, Ad5/3D24pIXcherry/SSTR, or Ad5/
3D24pIXcherry vector. Uninfected cells (mock) were used as a negative
control, whereas A-427-7, which stably express SSTR2, were used as a
positive control. Binding of 125I-Tyr11-SST-14 to the membranes in the
absence or presence of 1 mg of Tyr11-SST-14 as a blocking agent was
performed. The data are plotted as the bound counts per minute (CPM)
for the mean 6 SD of triplicate measurements. B, Representative
homologous competitive binding curves using 125I-Tyr11-SST-14 on
SKOV3.ip1 cell membranes that had been infected with either Ad5/
SSTRpIXcherry or Ad5/3D24pIXcherry/SSTR. The data represent the
counts per minute of radioligand bound in the presence of various
concentrations of block for triplicate data points 6 SD.

Evaluation of Oncolytic Effects of CRAd Vectors In
Vitro
The oncolytic effects of Ad5/3D24pIXcherry/SSTR vector
were assessed in SKOV3.ip1 cells with respect to that of
Ad5/3D24pIXcherry and Ad5/3D24 CRAd or replicationdeficient Ad5/3-SSTRpIXcherry control vectors by comparing cell viability and cell monolayer integrity 7 days

The utility of our dual imaging approach to detect CRAd
vector localization and persistence in vivo was evaluated in a
mouse model of subcutaneous tumor xenografts established
using SKOV3.ip1 ovarian cancer cells as described previously.43 To detect virus-mediated SSTR2 expression, we
analyzed systemic biodistribution of 64Cu-CB-TE2A-Y3TATE ligand 4 and 8 days following intratumoral injection
of Ad5/3D24pIXcherry/SSTR, Ad5/3D24pIXcherry CRAd, or
replication-deficient Ad5/3-SSTRpIXcherry vector. Figure 6,
A and B, illustrates the radioactivity distribution between
various organs and tissues collected 4 hours after intravenous
administration of radiolabeled SST analogue, which has been
carried out 4 and 8 days subsequent to virus injections. As
can be seen in Figure 6, C and D, the levels of 64Cu-CBTE2A-Y3-TATE uptake detected in tumors injected with
either virus were somewhat higher on day 4 than on day 8.
Figure 6C shows the significantly greater (p # .05)
radioligand uptake by tumors injected with either Ad5/3SSTRpIXcherry (3.63 6 2.45 %ID/g on day 4 and 2.88 6
1.52 %ID/g on day 8) or Ad5/3D24pIXcherry/SSTR (2.93 6
0.82 %ID/g on day 4 and 1.82 6 0.63 %ID/g on day 8)
compared to the background level detected in Ad5/
3D24pIXcherry-injected tumors (1.27 6 0.22 %ID/g on
day 4 and 0.83 6 0.25 %ID/g on day 8). Thus, these data
indicate that the specific uptake of radiolabeled ligand was
observed at both time points in tumors injected with Ad5/3SSTRpIXcherry and Ad5/3D24pIXcherry/SSTR vectors
expressing SSTR2 but not with Ad5/3D24pIXcherry control
(see Figure 6, C and D). Although it was not statistically
significant, somewhat lower radioligand uptake was detected
in tumors that were injected with Ad5/3D24pIXcherry/
SSTR CRAd compared to replication-incompetent Ad5/3SSTRpIXcherry vector on days 4 (p 5 .43) and 8 (p 5 .07).
Interestingly, these results did not correlate with improved
radioligand binding to the cells infected with CRAd compared
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in Figure 7A, the fluorescent signal generated by replicationdeficient Ad5/3-SSTRpIXcherry vector was localized in a
single spot within the tumor, whereas injection with
Ad5/3D24pIXcherry/SSTR and Ad5/3D24pIXcherry CRAd
resulted in markedly increased fluorescent area and intensity
in a majority of the tumors. This observation strongly
suggests that efficient replication of CRAd vectors occurred
during the 7 days following virus administration and
resulted in virus amplification wherein viral progeny could
be detected by spectral imaging compared to a nonreplicating Ad5/3-SSTRpIXcherry control. The mean fluorescent
light intensity was calculated based on images acquired at
different wavelengths, and the data presented in Figure 7B
show that fluorescent signal generated in Ad5/3D24pIXcherry/SSTR-injected tumors was amplified 5.3-fold
compared to the tumors injected with replication-deficient
vector (p 5 .018). The control Ad5/3D24pIXcherry CRAd
showed 2.6-fold enhanced fluorescent signal compared
to nonreplicating vector (p 5 .04) and somewhat lower
fluorescence than Ad5/3D24pIXcherry/SSTR CRAd (not
statistically significant, p 5 .15).
Ad Genome Quantification in Tumors
Figure 5. Analysis of oncolytic effects of Ad5/3D24pIXcherry/SSTR
vector. Monolayers of SKOV3ip.1 cells plated in a 96-well plate were
infected with Ad5/3D24pIXcherry/SSTR, Ad5/3D24pIXcherry, and Ad5/
3D24 CRAd or control replication-deficient Ad5/3-SSTRpIXcherry
vector at the indicated multiplicities of infection (MOIs). The oncolytic
effects of CRAd vectors were assessed by determining cell viability and cell
monolayer integrity 7 days postinfection. A, The virus-induced cell killing
was measured using cell proliferation assay by recording absorbance at
490 nm with a 96-well plate reader. The data are presented as the
percentages of viable cells in monolayers infected with each viral dose that
were determined with respect to the uninfected control set as 100%. B,
The integrity of cell monolayers was determined by staining adherent cells
with crystal violet. The stained monolayers were scanned using a plate
reader set at 565 nm to calculate the percentage of cell density in
monolayers infected with each viral dose that were determined with
respect to the uninfected control. Each data point represents mean 6 SD
(some error bars are smaller than the symbols).

to replication-incompetent vector expressing SSTR2 that was
observed in vitro (see Figure 4B).
Noninvasive Optical Imaging of Intratumoral CRAd
Amplification
To evaluate virus replication and spread within the tumors
in vivo, we employed noninvasive optical imaging to detect
fluorescent light signal 7 days after administration of Ad
vector particles labeled with mCherry protein. As can be seen

We used quantitative TaqMan real-time PCR to assess the
viral genome copy numbers in tumors harvested for
radioligand biodistribution assay. As illustrated in Figure 8,
the copy number of both CRAd genomes detected in tumors
at 4 and 8 days postinjection was markedly increased
compared to the replication-deficient Ad5/3-SSTRpIXcherry
control. However, the number of Ad5/3D24pIXcherry/SSTR
CRAd and nonreplicating Ad5/3-SSTRpIXcherry genomes
was decreased sixfold from days 4 to 8 (p 5 .009), whereas
the amount of Ad5/3D24pIXcherry CRAd remained the
same. This assay showed at least fivefold amplification
of Ad5/3D24pIXcherry/SSTR CRAd compared to nonreplicating Ad5/3-SSTRpIXcherry vector (p 5 .008) at both
time points, which correlates with a 5.3-fold increase in
fluorescent light signal generated by Ad5/3D24pIXcherry/
SSTR CRAd relative to the nonreplicating control observed
on day 7 postinjection (see Figure 7B). These data clearly
demonstrate a superior CRAd vector persistence subsequent
to intratumoral administration with respect to replicationincompetent Ad.
PET Imaging of Ad5/3D24pIXcherry/SSTR CRAd
To test whether SSTR2 gene transfer could be used to
image CRAd vector in vivo, the mice were injected
intratumorally with Ad5/3D24pIXcherry/SSTR or Ad5/
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Figure 6. Biodistribution of 64CuCB-TE2A-Y3-TATE in mice bearing
subcutaneous tumor xenografts. Subcutaneous tumor xenografts established on the rear flank of a female
nude mouse using SKOV3.ip1 cells
were directly injected with equal doses
(3 3 1010 viral particles/tumor) of
Ad5/3-SSTRpIXcherry, Ad5/3D24pIXcherry/SSTR, or Ad5/3D24pIXcherry
vector. 64Cu-CB-TE2A-Y3-TATE (5 mCi)
was injected via the tail vein 4 or 8 days
later, and mice were sacrificed in 4 hours
(n 5 5 for each group) to determine the
biodistribution of radioactivity. The data
are presented as the %ID/g 6 SD
detected in the indicated organs and
tumors 4 (A) and 8 (B) days following
virus administration. C, Analysis of the
tumor uptake of 64Cu-CB-TE2A-Y3TATE is shown. Each bar represents the
cumulative mean % ID/g 6 SD (*p #
.05). D, Analysis of the 64Cu-CB-TE2AY3-TATE uptake per tumor is shown.
Each bar represents the cumulative mean
% ID/tumor 6 SD (*p # .05).

3D24pIXcherry vector. MicroPET/computed tomography
(CT) revealed tumor accumulation of 64Cu-CB-TE2A-Y3TATE 1 hour postinjection in tumors injected with Ad5/
3D24pIXcherry/SSTR vector 4 days earlier. The smallanimal PET/CT images presented in Figure 9A show that
SSTR2 ligand uptake is observed in the tumors that received
Ad5/3D24pIXcherry/SSTR CRAd, whereas tumors that were
injected with Ad5/3D24pIXcherry CRAd serving as a
negative control did not show distinguishable uptake.
Clearance of 64Cu-CB-TE2A-Y3-TATE is observed through

the liver and kidneys, which match the biodistribution
results. Figure 9B shows the SUV analysis from the PET/CT
studies. We observed a 2.1-fold increase in 64Cu-CB-TE2AY3-TATE uptake in the tumors that were injected with Ad5/
3D24pIXcherry/SSTR vector compared to the background
uptake detected in tumors injected with Ad5/3D24pIXcherry
control, respectively. Although these data show that we can
visualize radioactive uptake in Ad5/3D24pIXcherry/SSTRinjected tumors compared to negative control CRAd in
individual animals, and the trend was for greater uptake by
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Figure 7. Noninvasive CRAd detection
with spectral imaging following intratumoral virus administration. Subcutaneous tumor xenografts were established
on both rear flanks of each female nude
mouse using SKOV3.ip1 cells and were
directly injected with equal doses (3 3
1010 viral particles/tumor) of Ad5/3SSTRpIXcherry, Ad5/3D24pIXcherry/
SSTR, or Ad5/3D24pIXcherry vector.
A, Sample images of three mice that
received the same Ad vector are shown
to illustrate signal variability between
different tumors and Ad vectors 7 days
postinjection. B, Light signals on original
unsaturated fluorescent images were
quantified using Molecular Imaging software, and integrated density was determined for each tumor. Each bar
represents the cumulative mean 6 SD
(*p , .05, **p . .05).

SUV analysis in the Ad5/3D24pIXcherry/SSTR-injected
tumors, this difference did not reach statistical significance
(p 5 .11). To verify the presence of Ad vectors in tumors,
which did not show significant uptake of 64Cu-CB-TE2AY3-TATE, we used fluorescence microscopy to detect
mCherry-positive cells in the samples of tumor tissue
extracted from mice 6 days later. We were able to visualize

Figure 8. Ad genome quantification in tumors. Total DNA isolated
from each tumor sample was analyzed by real-time PCR with primers
and probe specific for the hexon gene and then normalized to the
amount of cellular DNA detected in the same sample with primers and
probe for human b-actin (housekeeping gene) using duplexing
TaqMan PCR settings. Each bar represents the cumulative mean Ad
genome copy number/ng b-actin DNA 6 SD (*p # .05).

the fluorescent cells in the tumors injected with Ad5/
3D24pIXcherry/SSTR or control Ad5/3D24pIXcherry CRAd
vector (Figure S1, online version only).

Discussion
The biological basis of the CRAd’s antineoplastic effect is
target cell selective replication whereby direct oncolysis
achieves specific tumor cell killing. Progeny virions
generated in this process may thereby maintain the
replicative cycle via lateral infection of adjoining tumor
cells. This novel paradigm of amplification has rationalized
the rapid translation of CRAd agents to the context of
human clinical trials for a variety of neoplastic disease
targets. In the aggregate, these human studies have
highlighted the overall safety of CRAd-based interventions.
On the other hand, very little information has derived
from these trials indicative of valid clinical efficacy. More
significantly, the absence of useful surrogate end points in
these human studies has further limited any insights into
the biological factors confounding CRAd function in the
context of human clinical employ.
The mandate to realize surrogate end points in the
context of human clinical trials with CRAd agents has thus
suggested the utility of imaging analysis. In theory, this
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Figure 9. A, Representative views of maximum-intensity projections
of PET images with coregistered computed tomography of mice
bearing SKOV3.ip1 tumors following 64Cu-CB-TE2A-Y3-TATE injection. The images show uptake of 64Cu-CB-TE2A-Y3-TATE in the
tumors injected 4 days earlier with Ad5/3D24pIXcherry/SSTR CRAd
(1) but not in the control tumors injected with Ad5/3D24pIXcherry
(2). The white arrows indicate the location of the tumors, the red
arrows indicate radioactive excretion through the bladder, and the
yellow arrows indicate radioactivity clearance via the liver and kidneys.
B, The standardized uptake value (SUV) analysis for the tumors
injected (n 5 3) with Ad5/3D24pIXcherry/SSTR and control Ad5/
3D24pIXcherry CRAd. Each bar represents the cumulative mean 6 SD
(p 5 .11).

type of assay could provide critical information with
respect to CRAd replication, amplification, and localization. These types of studies could thereby provide key
insight into CRAd function in a human clinical context.
On this basis, it can be understood that the key attributes
of a monitoring system for CRAds would embody the
following capacities: (1) direct and dynamic readout of
viral replication, (2) direct and dynamic detection of viral
spread/lateralization, and (3) noninvasive imaging readout
capacity. Of note, these capacities must be achieved in the
context of not perturbing the virion’s essential infectious
activity, which provides the basis for CRAd antitumor
potency.
To address this key issue, we developed a novel CRAd
vector featuring multimodality imaging capacity, which
involves transient SSTR2 reporter gene expression compatible with gamma ray, SPECT, or PET detection and
fluorescent labeling based on structural incorporation of
mCherry protein into the viral capsid, allowing for optical
detection. We hypothesized that this approach would
provide the basis for deriving useful surrogate end-point
readouts, allowing valid imaging analysis of a human
CRAd intervention for carcinoma of the ovary. In this
regard, we previously demonstrated the feasibility of using
the direct labeling system achievable via genetic fusion of
minor capsid protein IX with mRFP1 or mCherry
fluorescent protein to dynamically monitor wild-type
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Ad5 vector29 and Ad5/3D24 CRAd30 replication in vivo
and to capture the kinetic changes in this process during
20 and 45 days, respectively.
In this study, we validated the utility of genetic pIXmCherry fusion in the context of our new Ad5/
3D24pIXcherry/SSTR CRAd to detect virus persistence
subsequent to intratumoral administration. Noninvasive
whole-body imaging analysis revealed at least a fivefold
increase in fluorescent light signal intensity in tumors
injected with Ad5/3D24pIXcherry/SSTR CRAd compared
to replication-incompetent Ad5/3-SSTRpIXcherry vector
(see Figure 7B), thereby indicating marked CRAd amplification relative to nonreplicating control during the 7 days
following virus administration. This result was confirmed by
viral genome quantification in tumors using quantitative
real-time PCR and demonstrated a superior CRAd vector
persistence subsequent to intratumoral administration with
respect to replication-incompetent Ad. We also noted a
sixfold decrease in Ad5/3D24pIXcherry/SSTR CRAd genome
copy number with respect to the control Ad5/3D24pIXcherry
CRAd on day 8 postinjection (see Figure 8). This decrease
was not consistent with an approximate twofold higher light
signal, which was detected by noninvasive imaging analysis of
intratumoral Ad5/3D24pIXcherry/SSTR CRAd amplification
compared to the control Ad5/3D24pIXcherry CRAd on day 7
postinjection (see Figure 7B). We speculate that the most
likely explanation for this inconsistency could be a proteolytic
degradation of mCherry protein during proliferation of
pIXmCherry-incorporating CRAd in vivo. We detected the
proteolytic degradation products of fluorescently labeled
pIX-mCherry fusion protein by Western blot analysis of
generated viruses (see Figure 2A), which was previously
attributed to Ad protease cleavage during capsid assembly
due to the presence of consensus recognition sites, (M/I/
L)XGX-G and (M/I/L)XGG-X,44 within fluorescent proteins
including enhanced green fluorescent protein and monomeric red fluorescent protein 1.42 Certain limitations are
associated with the use of fluorescence imaging in our genetic
capsid labeling system. The detection depth associated with
current fluorescence-based optical imaging technology
remains limited.45 Additionally, the possibility of achieving
tomographic data from fluorescence imaging for volumetric
quantification is still under development and not widely
available.46,47 As a result, conventional fluorescence imaging
is presently limited to application for superficial or accessible
tumors and would not be adequate for accurate quantification of volumetric fluorescence signals. Despite these shortcomings, optical imaging is less expensive and more
convenient than many other imaging modalities and therefore can serve as an attractive alternative in preclinical studies
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of fluorescently labeled CRAd because light penetration in
small animals is less of a concern than in humans. Our
laboratory and others have recently begun to explore the
functional utility of modifying Ad tropism for applied
human interventional contexts. For these studies, both
preclinical and clinical analyses of viral particle biodistribution as well as reporter gene locale and persistence are
sought. The capsid label provides a facile means to monitor
vector particle biodistribution, as we have shown.25
Although this method cannot be employed for all cancer
contexts where CRAd agents would be employed, we have
found this adjunctive reporter to allow the derivation of
useful data in the context of our ovarian cancer models. In
this regard, alternative imaging reporters that may be more
practical for deeper tissue detection, which include firefly
luciferase48 and the herpes simplex virus type 1 thymidine
kinase (HSV1-tk) gene,49 were also considered for genetic
capsid labeling.27,28,50
Of note, nuclear imaging has received much attention
because it is highly quantitative and sensitive and is directly
applicable to clinical trials. The HSV1-tk gene and its
mutants have been studied extensively and used for PET
with various radiolabeled substrates to image gene transfer
mediated by replication-deficient Ad vector in mice,51–54
nonhuman primates,55 and liver cancer patients.56 The
feasibility of using the HSV1-tk gene to monitor antitumoral effects of armed CRAd has recently been demonstrated in a murine model of pancreatic cancer57 and
following direct intrapancreatic virus injection in a
preclinical study in a dog model.58 The sodium iodide
symporter (NIS) is one of several human genes that are
being developed for nuclear imaging with radioiodide59 and
has been extensively employed for imaging of oncolytic Ad
vectors in animal models of human cancer60–67 and phase I
clinical trials in prostate cancer patients by SPECT.68
Our group and others have focused on using human
SSTR2, a member of the G protein–coupled receptor family,
for imaging of gene transfer using gamma camera, SPECT,
and PET.24,69–74 Although both NIS and HSV1-tk derivatives
have been investigated for imaging of oncolytic vectors based
on herpes virus,75 vesicular stomatitis virus,76 vaccinia
virus,77–81 measles virus,82–87 and Ad60–68 in vivo, the use
of SSTR2 reporter has been limited to replication-deficient
Ad24,69–74 and vaccinia virus88 to date. To assess the utility of
SSTR2 reporter in the context of CRAd vector, we studied
whether the oncolytic viral effects can interfere with SSTR2
imaging fidelity by comparing the engineered Ad5/
3D24pIXcherry/SSTR CRAd and replication-deficient Ad5/
3-SSTRpIXcherry control side by side for SSTR2 expression
and tracer binding efficiencies in vitro and in vivo.

Analysis of SSTR2 expression showed that Ad5/
3D24pIXcherry/SSTR infection of SKOV3.ip1 cells resulted
in up to eightfold SSTR2 upregulation compared to Ad5/
3-SSTRpIXcherry vector (see Figure 3B). The in vitro
binding studies showed that SSTR2 was functional as it
specifically bound 125I-Tyr11-SST-14 tracer, resulting in
almost a twofold increase in receptor concentration (Bmax)
observed in cells infected with Ad5/3D24pIXcherry/SSTR
CRAd compared to Ad5/3-SSTRpIXcherry control (see
Figure 4B). Biodistribution studies revealed specific uptake
of 64Cu-CB-TE2A-Y3-TATE tracer into SKOV3.ip1
tumors directly injected with Ad5/3D24pIXcherry/SSTR
or Ad5/3-SSTRpIXcherry vector relative to control tumors
injected with Ad5/3D24pIXcherry CRAd (see Figure 6, C
and D). These studies demonstrated a 2.3- and 2.2-fold
increase in tracer uptake in tumors 4 and 7 days after
injection with Ad5/3D24pIXcherry/SSTR compared to the
control Ad5/3D24pIXcherry CRAd. Interestingly, these
somewhat higher, 2.8- and 3.4-fold, increases in tracer
uptake were detected in tumors injected with nonreplicating Ad5/3-SSTRpIXcherry vector (3.6% ID/g on day 4,
2.8% ID/g on day 8) with respect to control tumors. We
previously demonstrated similar tumor uptake (1.3% ID/g)
6 hours after injection of 111In-DTPA-D-F1-octreotide
in mice bearing A-427 tumors directly injected with
replication-deficient AdSSTR2.70,89 McCart and colleagues
reported tumor uptake of approximately 1% ID/g at 4 and
24 hours after injection of 111In-DTPA-D-F1-octreotide in
mice that carried subcutaneous MC38 tumors and that had
received an intraperitoneal injection of oncolytic vaccinia
virus encoding SSTR2 6 days earlier.88 Yang and colleagues
reported that HT1080 tumor xenografts stably expressing
SSTR2 had 111In-DTPA-D-F1-octreotide uptake of
approximately 1% ID/g 24 hours after injection.90 Thus,
our results are comparable to those of other studies
evaluating the uptake of 111In-labeled SST analogues in
tumors induced to express SSTR2. Analysis of noninvasive
optical imaging, viral genome quantification, and biodistribution data indicates that a twofold increase in SSTR2
concentration mediated by Ad5/3D24pIXcherry/SSTR CRAd
with respect to Ad5/3-SSTRpIXcherry control in vitro (see
Figure 4B), along with superior CRAd persistence observed in
vivo (see Figure 7B and Figure 8), did not translate to
augmented tracer uptake in tumors injected with CRAd
relative to replication-incompetent vector (see Figure 6).
Similar to the previous studies,70,72 there was increased spleen
accumulation of 64Cu-CB-TE2A-Y3-TATE after injection of
Ad5/3-SSTRpIXcherry or Ad5/3D24pIXcherry/SSTR compared to Ad5/3D24pIXcherry control. This is likely due to Ad
infection of these organs even though virus was injected
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intratumorally. Other studies have shown that Ad vectors can
‘‘leak’’ from the tumor after direct intratumoral administration and infect the liver and spleen because of Ad natural
tropism for these normal tissues.91–93
Although our PET/CT imaging studies demonstrated
that Ad5/3D24pIXcherry/SSTR-injected tumors can be
visualized in individual animals and the trend was for
greater radioactive uptake by SUV analysis compared to
control CRAd, this difference did not reach statistical
significance. Since the magnitude of the differences
observed between the experimental and control constructs
remains to be a concern for clinical translation, we believe
that the radioligand-CRAd combination used in this study
may not be the one to move forward into clinical trials and
a more optimized combination would be expected to give
a better differential. We envision that during clinical
application of this technology, imaging would be performed prior to virus administration to determine the
baseline uptake. Imaging would then be performed at time
points after CRAd administration to determine if significant reporter gene transfer has occurred.
Although SSTR2 was not employed previously for CRAd
monitoring, several groups reported the use of human NIS
as a reporter gene for imaging of various CRAd agents
following intratumoral injection in animal models of
colorectal,63,65 prostate,60,66,67,94–96 and peritoneal ovarian
cancer.62 These SPECT imaging studies show that human
NIS expression reaches a peak 2 to 4 days after intratumoral
injection, followed by a sharp disappearance of human NIS–
dependent accumulation of radiotracer. A similar kinetic
has been reported by Barton and colleagues,97 using an
oncolytic Ad agent armed with two therapeutic suicide
genes and the human NIS reporter gene in a recent first
phase I trial, which demonstrated that human NIS
expression can be measured noninvasively in the human
prostate by SPECT.68 These data are consistent with our
PET imaging results and indicate that CRAd presence in
tumors can be detected by SPECT/PET during the early
stages of virotherapy treatment. However, as viral oncolysis
creates tumor destruction, the imaging system fails to
correlate with the magnitude of CRAd amplification
because intact cells are required for expression of HSV1tk, human NIS, and SSTR2 reporter gene products and their
physiologic protein functions. In the case of fluorescent
reporters, it is likely that these proteins will continue to emit
fluorescence on stimulation even after release by dead cells.
These studies have demonstrated that each reporter
exhibited limited functionality in the CRAd context in
vivo, thus suggesting that the use of a proposed dual
imaging approach combining both PET and optical CRAd
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detection should provide the technical basis of adaption
for a range of preclinical and clinical applications. A
rationale for combining two different imaging reporters is
to exploit the inherent advantages of one modality to
compensate for the limitations of another. Despite the fact
that nuclear imaging has the advantages of being highly
sensitive and quantitative, it is expensive and does not
have the resolution for single-cell imaging. Although the
sensitivity of optical probes decreases with the depth of
tissue, optical imaging is cost-effective and sensitive for
surface detection and can be used for single-cell imaging.98
Therefore, these optical and nuclear imaging reporters can
complement each other in preclinical tumor models for
the imaging of cancer therapy.99,100 Our study demonstrated the feasibility of monitoring CRAd persistence and
biodistribution using a dual imaging vector strategy in the
context of intratumoral virus administration, thus illustrating its utility for advanced CRAd development and
suggesting that it could also be applicable for monitoring
the effects of CRAd virotherapy in patients via imaging
modalities currently available within the clinical setting.
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SUPPLEMENTARY MATERIAL

Figure S1. Representative images of mCherry-positive cells visualized
using fluorescence microscopy in the tumor tissue extracted from mice
6 days after injection of Ad5/3D24pIXcherry/SSTR (A) or control Ad5/
3D24pIXcherry (B). The images of fluorescent cells are shown at a
magnification of 1003. The scale bar represents 20 mm.

19

